Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells $24,583.02 in Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Lauren Merendino sold 3,927 shares of the business’s stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $6.26, for a total transaction of $24,583.02. Following the completion of the sale, the insider now directly owns 35,161 shares in the company, valued at approximately $220,107.86. This trade represents a 10.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Day One Biopharmaceuticals Stock Performance

Shares of NASDAQ:DAWN traded up $0.23 during midday trading on Monday, reaching $6.48. 1,811,522 shares of the company’s stock traded hands, compared to its average volume of 1,107,801. Day One Biopharmaceuticals, Inc. has a one year low of $6.08 and a one year high of $16.76. The company has a market cap of $656.83 million, a price-to-earnings ratio of -6.29 and a beta of -1.24. The stock has a 50 day moving average of $7.44 and a 200 day moving average of $10.77.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its earnings results on Tuesday, May 6th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.11. The company had revenue of $30.76 million for the quarter, compared to analysts’ expectations of $30.28 million. Sell-side analysts predict that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. purchased a new stake in shares of Day One Biopharmaceuticals in the fourth quarter worth $27,000. R Squared Ltd purchased a new stake in Day One Biopharmaceuticals during the fourth quarter valued at $31,000. Quantbot Technologies LP bought a new position in shares of Day One Biopharmaceuticals in the 1st quarter valued at about $82,000. Pallas Capital Advisors LLC purchased a new position in shares of Day One Biopharmaceuticals in the 1st quarter worth approximately $87,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new position in Day One Biopharmaceuticals during the first quarter worth $88,000. 87.95% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

DAWN has been the subject of a number of recent research reports. The Goldman Sachs Group reduced their price objective on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating for the company in a research note on Tuesday, March 25th. Needham & Company LLC lowered their target price on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, April 3rd. Wedbush reaffirmed an “outperform” rating and issued a $25.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday, May 7th. Finally, JPMorgan Chase & Co. dropped their price objective on Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating for the company in a research note on Wednesday, March 5th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $30.57.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.